RxDoctor Payments DataLook up a doctor →

Phillip Wise, MD

Urology · Grand Rapids, MINPI 1124124086

Payments from drug & device makers

$28,271in general payments, 2019–2025

Across 350 payments — averaging $80.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Great Lakes Medical Services, LLC$17K
  • Teleflex LLC$2K
  • Boston Scientific$1K
  • Sumitomo Pharma America, Inc.$648
  • Coloplast$592
  • Neotract Inc.$585
  • plus $6K from 44 others

What the payments were for

  • Speaking & faculty fees$8293%
  • Travel & lodging$1,7956%
  • Food & beverage$9,57834%
  • Education$450%
  • Ownership interest$16,02457%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,271 in reported general payments places this provider in the 90th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$132,446
Medicare patients
236
Services billed
3,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide73$969,042
OrgovyxRelugolix101$257,901
GemtesaVibegron68$66,380
MyrbetriqMirabegron42$29,230
Tamsulosin Hcl342$8,112
Finasteride87$1,771
Trospium Chloride13$901
Dutasteride34$855
Testosterone13$827
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$314
Oxybutynin Chloride14$266
Cephalexin40$216
Ciprofloxacin Hcl24$154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$340$998,272115 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$648$324,281169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 400 urology providers in Michigan.

Other urology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →